Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go:
Stretch
investment:
Withheld
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
Customers can receive free parking at an airport by simply allowing others to rent out their vehicles, instead of leaving their cars idle in the airport cark park. ForestCar aim to help reduce harmful vehicle emission and are a part of a reforestation programme whereby a share of their revenue is invested in restoring global rainforests.
days to go:
Expired
investment:
£210,000
Auto Lease Compare is a company that uses a web-based platform to provide business services of leasing cars in the UK market. The company is on a mission to transform the growing UK car leasing industry. They are currently operating in a leasing & rental market worth £49 billion in the UK alone. Auto Lease Compare have increased their users to 40,000 on the platform and have also partnered with some of the UK’s leading leasing companies. With the investment, the company will grow its business by revamping and upgrading the website, executing a strong marketing strategy and increasing brand awareness.
days to go:
Expired
investment:
£111,860
Car Trust are a newly launched website backed by a comprehensive strategic plan and a motivated team. Users are able to buy and sell vehicles privately using the secure FCA authorised platform. Funds are being raised for marketing and product development.
days to go:
Expired
investment:
£22,750
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
miiCARE is a MedTech specialising in AI applied to geriatrics (elderly care). Its key product miiCUBE offers cutting-edge home-based and customised healthcare, helping the elderly enjoy their independence while being comprehensively connected to their families, friends, and neighbours. The company aims to provide these benefits to one billion people by 2028, comprising older people, family members and carers. Till date, miiCARE has secured partnerships with the UK’s largest NHS trust, Ebbsfleet Garden City, O2, Bristol Careline and Microsoft, and won multiple social impacts and digital health awards during the last 12 months. Funds raised will be used mainly for fulfilling pre-orders and close interests for large contracts with corporates, marketing and logistics, product development, sales and salaries.
days to go:
Expired
investment:
£103,672
GymBuddy is an online platform that enables consumers to find, book, and attend a gym location, services, or products offered and operated by fitness studios, gyms, trainers, venues, or other third parties. Users can easily, through filtered searches on the app, view descriptions, and contact information of specialists within the fitness industry such as personal trainers, nutritionists, and physiotherapists. The UK fitness industry alone is currently worth over £5 billion. Based on recent statistics, the average gym membership in the UK costs members £40 a month, which often ties them into lengthy contracts. The GymBuddy app will enter the Health & Fitness club sector as a multi-gym membership feature that gives users access to gyms and various fitness plans, without the need for bricks-and-mortar locations under its brand. The company is seeking an investment of £400,000 to expand its brand identity and bring more users to its ecosystem to generate profits.
days to go:
Expired
investment:
Withheld
